Management of hemostasis disorders after extracorporeal circulation. A clinical therapy algorithm;Gerinnungsmanagement bei eingriffen mit extrakorporaler zirkulation. Klinischer therapiealgorithmus

Anaesthesist

Volumn 57, Issue 4, 2008, Pages 374-381

  Jambor C ^a   Bremerich, D ^b   Moritz, A ^a   Seifried, E ^c   Zwissler, B ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b St Vincenz Krankenhaus   (Germany)

^c University of Ulm   (Germany)

Author keywords

Antifibrinolytics; Cardiac surgery; Coagulopathy; Extracorporeal circulation; Management of coagulation disorders

Indexed keywords

AMINOCAPROIC ACID; ANTITHROMBIN; APROTININ; BLOOD CLOTTING FACTOR 7A; DESMOPRESSIN; FIBRINOGEN; HEPARIN; PROTHROMBIN COMPLEX; TRANEXAMIC ACID;

ALGORITHM; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BLOOD GAS ANALYSIS; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; EXTRACORPOREAL CIRCULATION; GLANZMANN DISEASE; HEART SURGERY; HEMOPHILIA; HUMAN; REOPERATION;

ALGORITHMS; ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; BLOOD GAS ANALYSIS; BLOOD TRANSFUSION; DEAMINO ARGININE VASOPRESSIN; EXTRACORPOREAL CIRCULATION; FIBRINOGEN; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; PARTIAL THROMBOPLASTIN TIME; PLASMA; PLATELET COUNT; POINT-OF-CARE SYSTEMS; POSTOPERATIVE COMPLICATIONS;

EID: 42249091687     PISSN: 00032417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00101-008-1336-8     Document Type: Article

References (44)

1. Spiess BD, Gillies BS, Chandler W, Verrier E (1995) Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 9: 168-173
2. Shore-Lesserson L, Manspeizer HE, Perio M de et al. (1999) Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 88: 312-319
3. Anderson L, Quasim I, Soutar R et al. (2006) An audit of red cell and blood product use after the institution of thromboelastometry in a cardiac intensive care unit. Transfus Med 16: 31-39
4. Nuttall GA, Oliver WC, Santrach PJ et al. (2001) Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology 94: 773-781; discussion 5A-6A
5. Royston D, Kier S von (2001) Reduced haemostatic factor transfusion using heparinase-modified thrombelastography during cardiopulmonary bypass. Br J Anaesth 86: 575-578
6. Welsby IJ, Jiao K, Ortel TL et al. (2006) The kaolin-activated thrombelastograph predicts bleeding after cardiac surgery. J Cardiothorac Vasc Anesth 20: 531-535
7. Koscielny J, Tempelhoff GF von, Ziemer S et al. (2004) A practical concept for preoperative management of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 10: 155-166
8. Henry DA, Moxey AJ, Carless PA et al. (2001) Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev: CD001886
9. Carless PA, Moxey AJ, Stokes BJ, Henry DA (2005) Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials. BMC Cardiovasc Disord 5: 19
10. Karkouti K, Beattie WS, Dattilo KM et al. (2006) A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion- risk cardiac surgery. Transfusion 46: 327-338
11. Paparella D, Brister SJ, Buchanan MR (2004) Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 30: 1873-1881
12. Horrow JC (1995) Antifibrinolytic therapy: treat whom and with what? J Clin Anesth 7: 690
13. Levy JH, Pifarre R, Schaff HV et al. (1995) A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 92: 2236-2244
14. Beierlein W, Scheule AM, Dietrich W, Ziemer G (2005) Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions. Ann Thorac Surg 79: 741-748
15. Mangano DT, Tudor IC, Dietzel C (2006) The risk associated with aprotinin in cardiac surgery. N Engl J Med 354: 353-365
16. BART (2006) Blood conservation using antifibrinolytics: A randomized trial in a cardiac surgery population - the BART study. http://www.controlled- trials.com/isrctn/trial/APROTININ/0/15166455.html
17. FDA (2006) Information for Healthcare Professionals Aprotinin Injection. http://www.fda.gov/cder/drug/InfoSheets/HCP/aprotininHCP.htm
18. Shigeta O, Kojima H, Hiramatsu Y et al. (1999) Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg 118: 354-360
19. Mochizuki T, Olson PJ, Szlam F et al. (1998) Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 87: 781-785
20. Mittermayr M, Margreiter J, Velik-Salchner C et al. (2005) Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem): an in vitro study. Br J Anaesth 95: 310-316
21. Chowdhury P, Saayman AG, Paulus U et al. (2004) Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 125: 69-73
22. Casbard AC, Williamson LM, Murphy MF et al. (2004) The role of prophylactic fresh frozen plasma in decreasing blood loss and correcting coagulopathy in cardiac surgery. A systematic review. Anaesthesia 59: 550-558
23. Stanworth SJ, Brunskill SJ, Hyde CJ et al. (2004) Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 126: 139-152
24. Hiippala S, Linko K, Myllyla G et al. (1995) Replacement of major surgical blood loss by hypo-oncotic or conventional plasma substitutes. Acta Anaesthesiol Scand 39: 228-235
25. Singbartl K, Innerhofer P, Radvan J et al. (2003) Hemostasis and hemodilution: a quantitative mathematical guide for clinical practice. Anesth Analg 96: 929-935
26. Heindl B, Delorenzo C, Spannagl M (2005) High dose fibrinogen administration for acute therapy of coagulopathy during massive perioperative transfusion. Anaesthesist 54: 787-790
27. Fries D, Krismer A, Klingler A et al. (2005) Effect of fibrinogen on reversal of dilutional coagulopathy: a porcine model. Br J Anaesth 95: 172-177
28. Hiippala ST (1995) Dextran and hydroxyethyl starch interfere with fibrinogen assays. Blood Coagul Fibrinolysis 6: 743-746
29. Gottumukkala VN, Sharma SK, Philip J (1999) Assessing platelet and fibrinogen contribution to clot strength using modified thromboelastography in pregnant women. Anesth Analg 89: 1453-1455
30. Calatzis A, Wittwer M, Krueger B (2004) A new approach to platelet function analysis in whole blood: the multiplate analyzer. Platelets 15: 485-486
31. Jambor C, Weber C, Gerhardt K, Zwissler B (2007) Sensitive detection of ASA effect by the novel point of care impedance aggregometer multiplate. Anesthesiology 107: A2129
32. Mannucci PM (1997) Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 90: 2515-2521
33. Parr KG, Patel MA, Dekker R et al. (2003) Multivariate predictors of blood product use in cardiac surgery. J Cardiothorac Vasc Anesth 17: 176-181
34. Burroughs AK, Matthews K, Qadiri M et al. (1985) Desmopressin and bleeding time in patients with cirrhosis. Br Med J (Clin Res Ed) 291: 1377-1381
35. Mannucci PM, Remuzzi G, Pusineri F et al. (1983) Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 308: 8-12
36. Dilthey G, Dietrich W, Spannagl M, Richter JA (1993) Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin. J Cardiothorac Vasc Anesth 7: 425-430
37. Vincentelli A, Susen S, Tourneau T le et al. (2003) Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 349: 343-349
38. Schulman S, Johnsson H (1991) Heparin, DDAVP and the bleeding time. Thromb Haemost 65: 242-244
39. Emeis JJ, Eijnden-Schrauwen Y van den, Hoogen CM van den et al. (1997) An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol 139: 245-256
40. Heymann C von, Redlich U, Jain U et al. (2005) Recombinant activated factor VII for refractory bleeding after cardiac surgery - a retrospective analysis of safety and efficacy. Crit Care Med 33: 2241-2246
41. Karkouti K, Beattie WS, Wijeysundera DN et al. (2005) Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 45: 26-34
42. Dzik WH (2006) Off-label reports of new biologics: exciting new therapy or dubious research? Examples from recombinant activated factor VII. J Intensive Care Med 21: 54-59
43. Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS (2005) Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 95: 596-602
44. O'Connell KA, Wood JJ, Wise RP et al. (2006) Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295: 293-298